跳到正文
原文
STAT· @statnews · X·· 2026-10-16AI 评分22
AI 导读

GV普通合伙人兼生命科学负责人David Schenkein与SV Health Investors合伙人Jamil Beg谈论中国对美国生物科技公司构成的竞争威胁。#STATSummit

正文

David Schenkein, general partner and life sciences lead at GV, and Jamil Beg, partner at SV Health Investors, talk about the competitive threats China poses to U.S. biotech companies. #STATSummit

来源:STAT · x.com